Vertex Pharmaceuticals Inc (VRTX)

[surf1944]

11:00AM Vertex Pharm reports Phase 3 STRIVE Study of VX-770 showed durable improvements in lung function and other measures of disease among people with a specific type of cystic fibrosis (VRTX) 48.53 +0.48 : Co announced the final results from its pivotal Phase 3 STRIVE study that evaluated VX-770, a medicine in development that targets the defective protein that causes cystic fibrosis (CF). STRIVE was designed to evaluate VX-770 among 161 people 12 years or older with a mutation known as G551D in the CF gene. Data from the study showed rapid improvements in lung function (FEV1) that were sustained through 48 weeks among those who received VX-770, compared to those treated with a placebo. Significant improvements in all key secondary endpoints were observed among people who received VX-770 compared to placebo. Adverse events that occurred more frequently among those treated with VX-770 compared to placebo were headache, upper respiratory tract infections, nasal congestion, rash, dizziness and bacteria in the sputum.